Klinische studies tumoren van blaas en urinewegen

Op deze pagina


Aligator OPTIMIZE-2 - A-22-1013-C-04

A single-arm, open-label, phase 2 multicenter study to evaluate the safety and efficacy of mitazalimab in combination with pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma after prior immune checkpoint inhibitor therapy


Fase II studie BT8009 en Pembrolizumab Urotheliale

TROPHY-01 - IMMU-132-06

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer.


There are currently no ongoing studies in our center.


AARDVARC - D8731C00002

A Phase 2, open-label, study to assess the efficacy, safety and tolerability of AZD4635 in combination with durvalumab and the combination of AZD4635 with cabazitaxel and durvalumab in patients who have progressive metastatic castrate­ resistant prostate cancer

DANUBE D419BC00001

A phase III, randomized, open-label, controlled, multi-center, global study of first-line MEDI4736 monotherapy and MEDI4736 in combination with tremelimumab versus standard of care chemotherapy in patients with unresectable stage IV urothelial bladder cancer

EV-301 7465-CL-0301

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

EV-302 SGN22E-003

An open-label, randomized, controlled phase 3 study of enfortumab vedotin administered in combination with pembrolizumab, with or without platinum chemotherapy, versus platinum-containing chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

FIGHT 205 INCB 54828-205

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

FORT-1 17403

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

IMVIGOR010 WO29636

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection

IMVIGOR130 WO30070

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

KEYNOTE-905 MK3475-905

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer


A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer

PROOF 302 QBGJ398-302

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations

SAUL MO29983

An open-label, single-arm, multicenter, safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

TROPiCS-04 - IMMU-132-13

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

Laatste aanpassing: 17 april 2023